Albumin coated trimethyl chitosan-based targeting delivery platform for photothermal/chemo-synergistic cancer therapy

Hu, Haiyan; Qi, Qi; Dong, Zhe; Yu, Xianglong; Mo, Yujia; Luo, Ju-Yuan; Wang, Yan; Du, Shouying; Lu, Yang

doi:10.1016/j.carbpol.2020.116335

Cited by 25 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abundant amino and hydroxyl groups on the chitosan skeleton represent more target parts of chemical modification, which improves water solubility and endow chitosan with some new functions, such as targeted and environmentally sensitive drug release, and enhances therapeutic effect and minimize side effects. The most common chitosan derivatives used as drug carriers include thiochitosan, trimethyl chitosan, carboxymethyl chitosan, ethylene glycol chitosan and so on ( Hu et al, 2020 ; Grosso and De-Paz, 2021 ; Li et al, 2021 ).…”

Section: Chitosan: Source Structure Physicochemical Properties and Ap...mentioning

confidence: 99%

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

Ding

Guo

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer has become a main public health issue globally. The conventional treatment measures for cancer include surgery, radiotherapy and chemotherapy. Among the various available treatment measures, chemotherapy is still one of the most important treatments for most cancer patients. However, chemotherapy for most cancers still faces many problems associated with a lot of adverse effects, which limit its therapeutic potency, low survival quality and discount cancer prognosis. In order to decrease these side effects and improve treatment effectiveness and patient’s compliance, more targeted treatments are needed. Sustainable and controlled deliveries of drugs with controllable toxicities are expected to address these hurdles. Chitosan is the second most abundant natural polysaccharide, which has excellent biocompatibility and notable antitumor activity. Its biodegradability, biocompatibility, biodistribution, nontoxicity and immunogenicity free have made chitosan become a widely used polymer in the pharmacology, especially in oncotherapy. Here, we make a brief review of the main achievements in chitosan and its derivatives in pharmacology with a special focus on their agents delivery applications, immunomodulation, signal pathway modulation and antitumor activity to highlight their role in cancer treatment. Despite a large number of successful studies, the commercialization of chitosan copolymers is still a big challenge. The further development of polymerization technology may satisfy the unmet medical needs.

show abstract

Section: Chitosan: Source Structure Physicochemical Properties and Ap...mentioning

confidence: 99%

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

Ding

Guo

2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Serum albumin preferentially accumulates at the site of the tumor site giving it good natural tumor targeting capabilities. [33][34][35] Thus, albumin-based NPs provide the basis for tumor-based accumulation. Therefore, loading ICG into albumin to form NPs could construct an optimized nanoplatform that can significantly enhance tumor diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Indocyanine Green-Based Theranostic Nanoplatform for NIR Fluorescence Image-Guided Chemo/Photothermal Therapy of Cervical Cancer

Ma¹,

Alifu²,

Du³

et al. 2021

IJN

View full text Add to dashboard Cite

Indocyanine green (ICG) is a favorable fluorescence nanoprobe for its strong NIR-I fluorescence emission and good photothermal capabilities. However, the stability and tumor targeting ability of ICG is poor, which limits its further applications. To further improve the photothermal and therapeutic efficiency of ICG, bovine serum albumin (BSA) was utilized to encapsulate the ICG and the chemotherapeutic drug doxorubicin (DOX) was loaded to form the BSA@ICG-DOX theranostic nanoplatform. Methods: In this study, ICG-loaded BSA nanoparticles (NPs) and the BSA@ICG-DOX NPs were fabricated using reprecipitation methods. Next, the tumour inhibition ability and biocompatibility of the NPs were evaluated. A subcutaneous xenografted nude mice model was established and imaging guided synergetic therapy was performed with the assistance of BSA@ICG-DOX NPs under 808 nm laser irradiation. Results: The BSA@ICG NPs exhibited strong NIR-I fluorescence emission, excellent photothermal properties, biocompatibility, and tumor targeting ability. To further improve the therapeutic efficiency, the chemotherapeutic drug doxorubicin (DOX) was loaded into the BSA@ICG NPs to form the BSA@ICG-DOX theranostic nanoplatform. The BSA@ICG-DOX NPs were spherical with an average size of ~194.7 nm. The NPs had high encapsulation efficiency (DOX: 19.96% and ICG: 60.57%), and drug loading content (DOX: 0.95% and ICG: 3.03%). Next, excellent NIR-I fluorescence and low toxicity of the BSA@ICG-DOX NPs were verified. Targeted NIR-I fluorescence images were obtained after intravenous injection of the NPs into the subcutaneous cervical tumors of the mice. Conclusion:To improve the anti-tumor efficiency of the ICG@BSA NPs, the chemotherapeutic drug DOX was loaded into the BSA@ICG NPs. The NIR excitation/emission and targeted BSA@ICG-DOX NPs enables high-performance diagnosis and chemo/photothermal therapy of subcutaneous cervical tumors, providing a promising approach for further biomedical applications.

show abstract

“…Moreover, due to its toxicity, insolubility, rapid metabolism and short half-life, the applications of BU for cancer treatment are limited. (Gao et al 2021a, b;Yang et al 2021a, b) Accordingly, multiple nanodelivery systems have been investigated for loading BU to achieve precise targeting, enhance its antitumor effects, reduce its toxicity, and prolong its half-life (Hu et al 2020;Zeng et al 2021).…”

Section: Discussionmentioning

confidence: 99%

Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer

Siddique

Fan

et al. 2023

Cancer Nano

View full text Add to dashboard Cite

Background Intraperitoneal metastasis is one of the major causes of the high mortality rate of ovarian cancer. Bufalin (BU) is an effective component of the traditional Chinese medicine Chansu that exerts antitumor effects, including metastasis inhibition. In our previous studies, we found that BU inhibited the migration and invasion of ovarian cancer cells. However, the application of BU is limited due to its insolubility, toxicity and imprecise targeting. The aim of this study was to use vitamin E succinate (VES)-grafted chitosan oligosaccharide (CSO)/arginine-glycine-aspartic acid peptide (RGD)-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) mixed micelles (VeC/T-RGD MMs) to deliver BU to ovarian cancer cells to inhibit intraperitoneal metastasis. Moreover, the toxicity of BU was reduced by coating it with the mixed micelles to increase its biocompatibility for practical applications. Results The BU-loaded VeC/T-RGD MMs (BU@MMs) had an average diameter of 161 ± 1.4 nm, a zeta potential of 4.49 ± 1.54 mV and a loading efficiency of 2.54%. The results showed that these micelles inhibited cell proliferation, induced apoptosis, and reduced the migration and invasion of A2780 and SKOV3 cells. Further studies indicated that BU@MMs enhanced the levels of e-cadherin and decreased the expression levels of N-cadherin, vimentin and Snail in vitro. In addition, the mixed micelles effectively enhanced the anticancer effect and inhibited intraperitoneal metastasis in intraperitoneal metastatic models. The BU@MMs exhibited fewer toxic side effects than BU, indicating better biocompatibility and biosafety for in vivo applications. Conclusions Our studies show that BU@MMs are a potential multifunctional nano-drug delivery system that can effectively inhibit the intraperitoneal metastasis of ovarian cancer.

show abstract

Albumin coated trimethyl chitosan-based targeting delivery platform for photothermal/chemo-synergistic cancer therapy

Cited by 25 publications

References 38 publications

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

Indocyanine Green-Based Theranostic Nanoplatform for NIR Fluorescence Image-Guided Chemo/Photothermal Therapy of Cervical Cancer

Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer

Contact Info

Product

Resources

About